永安药业
(002365)
| 流通市值：20.20亿 | | | 总市值：24.40亿 |
| 流通股本：2.44亿 | | | 总股本：2.95亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 618,715,718.75 | 425,816,581.92 | 196,644,532.11 | 972,890,144.84 |
| 营业收入 | 618,715,718.75 | 425,816,581.92 | 196,644,532.11 | 972,890,144.84 |
| 二、营业总成本 | 583,875,551.55 | 387,989,771.47 | 175,009,541.52 | 965,619,212.39 |
| 营业成本 | 471,873,467.46 | 313,331,804.97 | 140,270,981.04 | 721,213,010.48 |
| 税金及附加 | 7,622,372.17 | 4,867,721.04 | 3,088,925.16 | 10,085,263.65 |
| 销售费用 | 11,887,942.78 | 7,878,264.03 | 3,928,698.55 | 54,500,064.25 |
| 管理费用 | 68,779,872.24 | 47,990,569.62 | 22,488,466.54 | 145,217,150.93 |
| 研发费用 | 30,378,183.79 | 21,546,474.74 | 10,019,915.12 | 41,500,983.96 |
| 财务费用 | -6,666,286.89 | -7,625,062.93 | -4,787,444.89 | -6,897,260.88 |
| 其中:利息费用 | 403,220.03 | 220,968.03 | 108,343.68 | 374,404.64 |
| 其中:利息收入 | 1,337,541.88 | 915,789.44 | 660,741.25 | 1,880,430.78 |
| 加:公允价值变动收益 | 494,831.48 | 3,773,828.96 | 3,122,732.45 | 11,825,152.12 |
| 加:投资收益 | 28,707,327.09 | 16,718,245.99 | 6,293,983.84 | 25,505,792.22 |
| 资产处置收益 | -724,228.32 | -541,060.98 | -50,262.02 | 45,015,736.27 |
| 资产减值损失(新) | -160,682.23 | - | - | -96,571,598.38 |
| 信用减值损失(新) | 239,415.41 | -1,356,018.82 | -1,039,676.14 | 1,762,158.53 |
| 其他收益 | 5,753,071.67 | 4,677,044.73 | 4,185,631.22 | 10,840,027.44 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 69,149,902.3 | 61,098,850.33 | 34,147,399.94 | 5,648,200.65 |
| 加:营业外收入 | 544,503.42 | 68,548.71 | 41,167.52 | 2,648,179.67 |
| 减:营业外支出 | 1,069,727.4 | 379,361.67 | 354,890.08 | 2,244,746.81 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 68,624,678.32 | 60,788,037.37 | 33,833,677.38 | 6,051,633.51 |
| 减:所得税费用 | 9,824,982.9 | 9,674,869.63 | 5,357,520.08 | 34,466,189.59 |
| 六、净利润 | 58,799,695.42 | 51,113,167.74 | 28,476,157.3 | -28,414,556.08 |
| 持续经营净利润 | 58,799,695.42 | 46,843,119.89 | 28,476,157.3 | -52,123,864.91 |
| 终止经营净利润 | - | 4,270,047.85 | - | 23,709,308.83 |
| 归属于母公司股东的净利润 | 61,855,243.42 | 52,485,217.27 | 28,680,093.28 | -12,312,563.51 |
| 少数股东损益 | -3,055,548 | -1,372,049.53 | -203,935.98 | -16,101,992.57 |
| (一)基本每股收益 | 0.21 | 0.18 | 0.1 | -0.04 |
| (二)稀释每股收益 | 0.21 | 0.18 | 0.1 | -0.04 |
| 八、其他综合收益 | -2,054,794.11 | -1,935,157.89 | -1,961,032.12 | 894,753.32 |
| 归属于母公司股东的其他综合收益 | -2,054,794.11 | -1,935,157.89 | -1,961,032.12 | 894,753.32 |
| 九、综合收益总额 | 56,744,901.31 | 49,178,009.85 | 26,515,125.18 | -27,519,802.76 |
| 归属于母公司股东的综合收益总额 | 59,800,449.31 | 50,550,059.38 | 26,719,061.16 | -11,417,810.19 |
| 归属于少数股东的综合收益总额 | -3,055,548 | -1,372,049.53 | -203,935.98 | -16,101,992.57 |
| 公告日期 | 2024-10-30 | 2024-08-28 | 2024-04-30 | 2024-04-19 |
| 审计意见(境内) | | | | 标准无保留意见 |